GPR55 and its interaction with membrane lipids: Comparison with other endocannabinoid-binding receptors

Current Medicinal Chemistry

Volumn 20, Issue 1, 2013, Pages 64-78

  Gasperi, V ^a   Dainese, E ^b,c   Oddi, S ^b,c   Sabatucci, A ^b   Maccarrone, M ^c,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cannabinoid receptors; Cholesterol; Endocannabinoids; GPR55; Lipid rafts; Plasma membranes

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 54; G PROTEIN COUPLED RECEPTOR 55; MEMBRANE LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ARTICLE; BIOLOGICAL ACTIVITY; BONE METABOLISM; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; ENERGY METABOLISM; HUMAN; INFLAMMATION; LIPID RAFT; NEOPLASM; NERVE FUNCTION; NOCICEPTION; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION; REPRODUCTION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DISCOVERY; ENDOCANNABINOIDS; HUMANS; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84872954488     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673130108     Document Type: Article

References (166)

1. Kano, M., Ohno-Shosaku, T.; Hashimotodani, Y.; Uchigashima, M.; Watanabe, M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev., 2009, 89(1), 309-380.
2. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
3. Mechoulam, R., S. Ben-Shabat, Hanus L, Ligumsky, M; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50(1), 83-90.
4. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. M.S.A., 2001, 98(7), 3662-3665.
5. Porter, A.C.; Sauer, J.M.; Knierman, M. D.; Becker, G.W.; Berna, M.J.; Bao, J.; Nomikos, G.G.; Carter, P.; Bymaster, F.P.; Leese, A.B.; Felder, C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301(3), 1020-1024.
6. Huang, S.M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T.J.; Krey, J.F.; Chu, C.J.; Miller, J.D.; Davies, S.N.; Geppetti, P.; Walker, J.M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. M.S.A., 2002, 99(12), 8400-8405.
7. De Petrocellis, L.; Di Marzo, V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 23(1), 1-15.
8. Brown, I.; Cascio, M.G.; Wahle, K.W.; Smoum, R.; Mechoulam, R.; Ross, R.A.; Pertwee, R.G.; Heys, S.D. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis, 2010, 31(9), 1584-1591.
9. Yang, R.; Fredman, G.; Krishnamoorthy, S.; Agrawal, N.; Irimia, D.; Piomelli, D.; Serhan, C.N. Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J. Biol. Chem., 2011, 286(36), 31532-31541.
10. Matsuda, L.A.; Lolait S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cD.N.A. Nature, 1990, 346(6284), 561-564.
11. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
12. Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.H.; George, S.R.; O'Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res., 1999, 64(2),193-198.
13. Lauckner, J.E.; Jensen, J.B.; Chen, H.Y.; Lu, H.C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. M.S.A., 2008, 105(7), 2699-2704.
14. McVey, D.C.; Schmid, P.C.; Schmid, H.H.; Vigna, S.R. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J. Pharmacol. Exp. Ther., 2003, 304(2), 713-722.
15. Nilius, B.; Vriens, J.; Prenen, J.; Droogmans, G.; Voets, T. TRPV4 calcium entry channel: a paradigm for gating diversity. Am. J. Physiol. Cell. Physiol., 2004, 286(2), C195-205.
16. Sun, Y.; Bennett, A. Cannabinoids: A New Group of Agonists of PPARs. PPAR Res. 2007, 2007, 23513.
17. Piomelli, D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 2003, 4(11), 873-884.
18. Klein, T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol., 2005, 5(5), 400-411.
19. Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Meozzi, P.A.; Myers, L.; Perchuk, A; Mora, Z; Tagliaferro, P.A.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Chirwa, S.S.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasenfitz, L.; Arinami, T.; Uhl, G.R. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N.Y. Acad. Sci., 2008, 1139, 434-449.
20. Viscomi, M.T.; Oddi, S.; Latini, L.; Pasquariello, N.; Florenzano, F.; Bernardi, G.; Molinari, M.; Maccarrone, M. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J. Neurosci., 2009, 29(14), 4564-4570.
21. den Boon, F.S.; Chameau, P.; Schaafsma-Zhao, Q.; van Aken, W.; Bari M.; Oddi, S.; Kruse, C.G.; Maccarrone, M.; Wadman, W.J.; Werkman, T.R. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. M.S.A., 2012, 109(9), 3534-3539.
22. Oddi, S.; Latini, L.; Viscomi, M.T.; Bisicchia, E.; Molinari, M.; Maccarrone, M. Distinct regulation of nNOS and iNOS by CB(2) receptor in remote delayed neurodegeneration J. Mol. Med. (Berl), 2012, 90(4), 371-387.
23. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, (168), 53-79.
24. Oldham, W.M.; Hamm, H.E. Heterotrimeric G protein activation by Gprotein-coupled receptors. Nat. Rev. Mol. Cell. Biol., 2008, 9(1), 60-71.
25. Katoh, H.; Aoki, J.; Yamaguchi, Y.; Kitano, Y.; Ichikawa, A.; Negishi, M. Constitutively active Galpha12, Galpha13, and Galphaq induce Rhodependent neurite retraction through different signaling pathways. J. Biol. Chem., 1998, 273(44), 28700-28707.
26. Yang, Z. Small GTPases, Versatile Signaling Switches in Plants. Plant Cell, 2002, 14(Supplement), 375-388.
27. Kurose, H. Galpha12 and Galpha13 as key regulatory mediator in signal transduction. Life Sci., 2003, 74(2-3), 155-161.
28. Bonhaus, D.W.; Chang, L.K.; Kwan, J.; Martin, G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther., 1998, 287(3), 884-888.
29. Bouaboula, M.; Poinot-Chazel, C.; Bourrié, B.; Canat, X.; Calandra, B.; Rinaldi-Carmona, M.; Le Fur, G.; Casellas, P. Activation of mitogenactivated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J., 1995, 312(Pt 2), 637-641.
30. Liu, J.; Gao, B.; Mirshahi, F.; Sanyal, A.J.; Khanolkar, A.D.; Makriyannis, A.; Kunos, G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J., 2000, 346(Pt 3), 835-840.
31. Diaz-Laviada, I.; Ruiz-Llorente, L. Signal transduction activated by cannabinoid receptors. Mini Rev. Med. Chem., 2005, 5(7), 619-630.
32. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A.L.; Mitchell, R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48(3), 443-450.
33. Starowicz, K., Nigam, S.; Di Marzo, V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther., 2007, 114(1), 13-33.
34. Roberts, J.C.; Davis, J.B.; Benham, C.D. [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain. Res., 2004, 995(2), 176-183.
35. Toth, A.; Boczan, J.; Kedei, N.; Lizanecz, E.; Bagi, Z.; Papp, Z.; Edes, I.; Csiba, L.; Blumberg, P.M. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res., 2005, 135(1-2), 162-8.
36. Moran, M.M.; McAlexander, M.A.; Bíró, T.; Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug. Discov., 2011, 10(8), 601-620.
37. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature, 2000, 405(6785), 421-424.
38. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
39. Bouaboula, M.; Hilairet, S.; Marchand, J.; Fajas, L.; Le Fur, G.; Casellas, P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol., 2005, 517(3), 174-181.
40. Gasperi, V.; Fezza, F.; Pasquariello, N.; Bari, M.; Oddi, S.; Agrò, A.F.; Maccarrone, M. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell. Mol. Life Sci., 2007, 64(2), 219-229.
41. Rockwell, C.E., Snider, N.T.; Thompson, J.T.; Vanden Heuvel, J.P.; Kaminski, N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol., 2006, 70(1), 101-111.
42. Rockwell, C.E.; Kaminski, N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin 2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther., 2004, 311(2), 683-690.
43. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. M.S.A., 1999, 96(24), 14136-14141.
44. Wise, A.; Brown, A.J. GlaxoSmithKline, Identification of modulators of GPR55 activity. Patent WO0186305, 2001.
45. Drmota, T.; Greasley, P.; Groblewski, T. AstraZeneca. Screening assays for cannabinoid-ligand type modulators of GPR55. Patent WO04074844, 2004.
46. Henstridge, C.M.; Balenga, N.A.; Ford, L.A.; Ross, R.A.; Waldhoer, M.; Irving, A.J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J., 2009, 23(1), 183-193.
47. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Abood, M.E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem., 2009, 284(43), 29817-29827.
48. [Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152(7), 1092-1101.
49. [Waldeck-Weiermair, M.; Zoratti, C.; Osibow, K.; Balenga, N.; Goessnitzer, E.; Waldhoer, M.; Malli, R.; Graier, W.F. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell. Sci., 2008, 121(10),1704-1717.
50. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D.G.; Caldwell, J.S.; Chen, Y.A. Lipid G-protein-coupled receptor ligand identification using beta -arrestin Pathhunter assay. J. Biol. Chem., 2009, 284(18), 12328-12338.
51. Johns, D.G.; Behm, D.J.; Walker, D.J.; Ao, Z.; Shapland, E.M.; Daniels, D.A.; Riddick, M.; Dowell, S.; Staton, P.C.; Green, P.; Shabon, M.; Bao, W.; Aiyar, N.; Yue, T.L.; Brown, A.J.; Morrison, A.D.; Douglas, S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol., 2007, 152(5), 825-831.
52. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362(4):928-934.
53. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem., 2009, 145(1), 13-20.
54. Ross, R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci., 2009, 30(3), 156-163.
55. Obara, Y.; Ueno, S.; Yanagihata, Y.; Nakahata, N. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells. PLoS One, 2011, 6(8):e24284.
56. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R.A.; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. M.S.A., 2009, 106(38),16511-16516.
57. Piñeiro, R.; Maffucci, T.; Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene, 2011, 30(2), 142-152.
58. Oka, S.; Kimura, S.; Toshida, T.; Ota, R.; Yamashita, A.; Sugiura, T. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogenactivated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J. Biochem., 2010, 147(5),671-678.
59. Huang, S.M.; Bisogno, T.; Petros, T.J.; Chang, S.Y.; Zavitsanos, P.A.; Zipkin, R.E.; Sivakumar, R.; Coop, A.; Maeda, D.Y.; De Petrocellis, L.; Burstein, S.; Di Marzo, V.; Walker, J.M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem., 2001, 276(46), 42639-42644.
60. Zhang, X.; Maor, Y.; Wang, J.F.; Kunos, G.; Groopman, J.E. Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br. J. Pharmacol., 2010, 160(7),1583-1594.
61. Huang, L.; Ramirez, J.C.; Frampton, G.A.; Golden, L.E.; Quinn, M.A.; Pae, H.Y.; Horvat, D.; Liang, L.J.; DeMorrow, S. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab. Invest., 2011, 91(7), 1007-10017.
62. Daly, C.J.; Ross, R.A.; Whyte, J.; Henstridge, C.M.; Irving, A.J.; McGrath, J.C. Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br. J. Pharmacol., 2010, 159(4),787-796.
63. Romero-Zerbo, S.Y.; Rafacho, A.; Díaz-Arteaga, A.; Suárez, J.; Quesada, I.; Imbernon, M.; Ross, R.A.; Dieguez, C.; Rodríguez de Fonseca, F.; Nogueiras, R.; Nadal, A.; Bermúdez-Silva, F.J. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol., 2011, 211(2), 177-185.
64. Fonseca, B.M.; Teixeira, N.A.; Almada, M.; Taylor, A.H.; Konje, J.C.; Correia-da-Silva, G. Modulation of the novel cannabinoid receptor -GPR55 -during rat fetoplacental development. Placenta, 2011, 32(6),462-469.
65. Greasley, P.; Åstrand, A.; Lindblom, A.; Sjöqvist, P.O.; Hjorth, S; Sjögren, S. In: A role for GPR55 in mediating blood pressure responses. Proceedings of the 18th Annual Symposium of the International Cannabinoid Research Society (ICRS) Aviemore, Scotland, June 25-29, 2008.
66. Gold, M.S.; Gebhart, G.F. Nociceptor sensitization in pain pathogenesis. Nat. Med., 2010, 16(11), 1248-1257.
67. Staton, P.C.; Hatcher, J.P.; Walker, D.J.; Morrison, A.D.; Shapland, E.M.; Hughes, J.P.; Chong, E.; Mander, P.K.; Green, P.J.; Billinton, A.; Fulleylove, M.; Lancaster, H.C.; Smith, J.C.; Bailey, L.T.; Wise, A.; Brown, A.J.; Richardson, J.C.; Chessell, I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139(1), 225-236.
68. Breen, C.; Brownjohn, P.W.; Ashton, J.C. The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neurosci. Lett., 2012, 508(2), 119-122.
69. McHugh, D.; Hu, S.S.J.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J.M.; Bradshaw, H.B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. B.M.C. Neurosci., 2010, 11, 44.
70. Vuong, L.A.; Mitchell, V.A.; Vaughan, C.W. Actions of N-arachidonylglycine in a rat neuropathic pain model. Neuropharmacology, 2008, 54(1), 189-193.
71. Walter, L.; Stella, N. Cannabinoids and neuroinflammation. Br. J. Pharmacol., 2004, 141(5), 775-785.
72. Zoeller, R.A.; Wightman, P.D.; Anderson, M.S.; Raetz, C.R. Accumulation of lysophosphatidylinositol in RAW 264.7 macrophage tumor cells stimulated by lipid A precursors. J. Biol. Chem., 1987, 262(35), 17212-17220.
73. Varga, K.; Wagner, J.A.; Bridgen, D.T.; Kunos, G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J., 1998, 12(11), 1035-1044.
74. Pietr, M., Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y.H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett., 2009, 583(12), 2071-2076.
75. Balenga, N.A.; Aflaki, E.; Kargl, J.; Platzer, W.; Schröder, R.; Blättermann, S.; Kostenis, E.; Brown, A.J.; Heinemann, A.; Waldhoer, M. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res., 2011, 21(10), 1452-1469
76. Aloe, L.; Bracci-Laudiero, L.; Bonini, S.; Manni, L. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy, 1997, 52(9), 883-994.
77. Cantarella, G.; Lempereur, L.; Presta, M.; Ribatti, D.; Lombardo, G.; Lazarovici, P.; Zappalà, G.; Pafumi, C.; Bernardini, R. Nerve growth factorendothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J., 2002, 16(10), 1307-1309
78. Cantarella, G.; Scollo, M.; Lempereur, L.; Saccani-Jotti, G.; Basile, F.; Bernardini, R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol., 2011, 82(4), 380-388.
79. Schicho, R.; Bashashati, M.; Bawa, M.; McHugh, D.; Saur, D.; Hu, H.M.; Zimmer, A.; Lutz, B.; Mackie, K.; Bradshaw, H.B.; McCafferty, D.M.; Sharkey, K.A.; Storr, M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm. Bowel Dis., 2011, 17(8),1651-1664.
80. Maccarrone, M.; Gasperi, V.; Catani, M.V.; Diep, T.A.; Dainese, E.; Hansen, H.S.; Avigliano, L. The endocannabinoid system and its relevance for nutrition. Annu. Rev. Nutr., 2010, 21(30), 423-440.
81. Moreno-Navarrete, J.M.; Catalán, V.; Whyte, L.; Díaz-Arteaga, A.; Vázquez-Martínez, R.; Rotellar, F.; Guzmán, R.; Gómez-Ambrosi, J.; Pulido, M.R.; Russell, W.R.; Imbernón, M.; Ross, R.A.; Malagón, M.M.; Dieguez, C.; Fernández-Real, J.M.; Frühbeck, G.; Nogueiras, R. The L-lysophosphatidylinositol/GPR55 system and its potential role in human obe sity. Diabetes, 2012, 61(2), 281-291.
82. Díaz-Arteaga, A.; Vázquez, M.J.; Vazquez-Martínez, R.; Pulido, M.R.; Suarez, J.; Velásquez, D.A.; López, M.; Ross, R.A.; de Fonseca, F.R.; Bermudez-Silva, F.J.; Malagón, M.M.; Diéguez, C.; Nogueiras, R. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes. Metab., 2012, 14(3), 234-243.
83. Mayas, C.L.; Moreno-Flores, M.T.; Avila, J.; Wandosell, F. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's diseaselike Tau phosphorylation. J. Biol. Chem., 1999, 274(52), 37046-37052.
84. Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol., 2008, 153(2), 182-188.
85. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. M.S.A., 2006, 103(3), 696-701.
86. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, M. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet., 2005, 14(22), 3389-3396.
87. Yamada, Y.; Ando, F.; Shimokata, H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int. J. Mol. Med., 2007, 19(5),791-801.
88. Maccarrone, M. Endocannabinoids: friends and foes of reproduction. Prog. Lipid. Res., 2009, 48(6), 344-354.
89. Acar, N.; Ustunel, I.; Demir R. Uterine natural killer (uNK) cells and their missions during pregnancy: a review. Acta Histochem., 2010, 113(2), 82-91.
90. Falasca, M.; Corda, D. Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur. J. Biochem., 1994, 221(1), 383-389.
91. Xiao, Y.; Chen, Y.; Kennedy, A.W.; Belinson, J.; Xu, Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. N.Y. Acad. Sci., 2000, 905, 242-259.
92. Shen, Z.Z.; Wu, M.; Elson, P.; Kennedy, AW.; Belinson, J.; Casey, G.; Xu, Y. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynaecol. Oncol., 2001, 83(1), 25-30.
93. Sutphen, R.; Xu, Y.; Wilbanks, G.D.; Fiorica, J.; Grendys, E.C. Jr.; LaPolla, J.P.; Arango, H.; Hoffman, M.S.; Martino, M.; Wakeley, K.; Griffin, D.; Blanco, R.W.; Cantor, A.B.; Xiao, Y.J.; Krischer, J.P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13(7), 1185-1191.
94. Ford, L.A.; Roelofs, A.J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D.G.; Irving, A.J.; Rogers, M.J.; Rajnicek, A.M.; Ross, R.A. A role for L-alphalysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol., 2010, 160(3), 762-771.
95. Andradas, C.; Caffarel, M.M.; Pérez-Gómez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzmán, M.; Sánchez, C. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via E.R.K. Oncogene, 2011, 30(2), 245-252.
96. Sharir, H.; Abood, M.E. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther., 2010, 126(3), 301-313.
97. Pérez-Gómez, E.; Andradas, C.; Flores, J.M.; Quintanilla, M.; Paramio, J.M.; Guzmán, M.; Sánchez, C. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene, 2012, doi: 10.1038/onc.2012.278.
98. Brown, D.A.; London, E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell. Dev. Biol., 1998, 14, 111-136.
99. Pike, L.J. Lipid rafts: bringing order to chaos. J. Lipid Res., 2003, 44(4), 655-667.
100. Dainese, E.; Oddi, S.; Maccarrone, M. Interaction of endocannabinoid receptors with biological membranes. Curr. Med. Chem., 2010, 17(14), 1487-1499.
101. Galbiati, F.; Razani, B.; Lisanti, M.P. Emerging themes in lipid rafts and caveolae. Cell, 2001, 106(4), 403-411.
102. Lingwood, D.; Ries, J.; Schwille, P.; Simons, K. Plasma membranes are poised for activation of raft phase coalescence at physiological temperature. Proc. Natl. Acad. Sci. M.S.A., 2008, 105(29), 10005-10010.
103. Ostermeyer, A.G.; Beckrich, B.T.; Ivarson, K.A.; Grove, K.E.; Brown, D.A. Glycosphingolipids are not essential for formation of detergent-resistant membrane rafts in melanoma cells. methyl-beta-cyclodextrin does not affect cell surface transport of a GPI-anchored protein. J. Biol. Chem., 1999, 274(48), 34459-34466.
104. Chen, X.; Jayne, L.M.; Barlow, D.J.; Morris, R.J.; Heenan, R.K.; Quinn, P.J. The structure of detergent-resistant membrane vesicles from rat brain cells. Biochim. Biophys. Acta, 2009, 1788(2), 477-483.
105. Xu, X.; London, E. The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. Biochemistry, 2000, 39(5), 843-849.
106. Hansen, G.H.; Niels-Christiansen, L.L.; Thorsen, E.; Immerdal, L.; Danielsen, E.M. Cholesterol depletion of enterocytes. Effect on the Golgi complex and apical membrane trafficking. J. Biol. Chem., 2000, 275(7), 5136-5142.
107. Bari, M.; Battista, N.; Fezza, F.; Finazzi-Agro, A.; Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J. Biol. Chem., 2005, 280(13), 12212-12220.
108. Bari, M.; Paradisi, A.; Pasquariello, N.; Maccarrone, M. Cholesteroldependent modulation of type 1 cannabinoid receptors in nerve cells. J. Neurosci. Res., 2005, 81(2), 275-22283.
109. Dainese, E.; Oddi, S.; Bari, M.; Maccarrone, M. Modulation of the endocannabinoid system by lipid rafts. Curr. Med. Chem., 2007, 14(25), 2702-2715.
110. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature, 1997, 387(6633), 569-572.
111. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell. Biol., 2000, 1(1), 31-39.
112. Michel,V.; Bakovic, M. Lipid rafts in health and disease. Biol. Cell., 2007, 99(3), 129-140.
113. Eroglu, C.; Brugger, B.; Wieland, F.; Sinning, I. Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts. Proc. Natl. Acad. Sci. M.S.A., 2003, 100(18), 10219-10224.
114. Song, K.S.; Li, S.; Okamoto, T.; Quilliam, L.A.; Sargiacomo, M.; Lisanti, M.P. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J. Biol. Chem., 1996, 271(16), 9690-9697.
115. Anderson, R.G.; Jacobson, K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science, 2002, 296(5574), 1821-1825.
116. Milligan, G.; Grassie, M.A.; Wise, A.; MacEwan, D.J.; Magee, A.I.; Parenti, M. G-protein palmitoylation: regulation and functional significance. Biochem. Soc. Trans., 1995, 23(3), 583-587.
117. Moffett, S.; Brown, D.A.; Linder, M.E. Lipid-dependent targeting of G proteins into rafts. J. Biol. Chem., 2000, 275(3), 2191-2198.
118. Shaul, P.W.; Smart, E.J.; Robinson, L.J.; German, Z.; Yuhanna, I.S.; Ying, Y.; Anderson, R.G.; Michel, T. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem., 1996, 271(11), 6518-6522.
119. Zacharias, D.A.; Violin, J.D.; Newton, A.C.; Tsien, R.Y. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science, 2002, 296(5569), 913-916.
120. McLaughlin, S.; Murray, D. Plasma membrane phosphoinositide organization by protein electrostatics. Nature, 438(7068), 605-611.
121. McMahon, H.T.; Gallop, J.L. Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature, 2005, 438(7068), 590-596.
122. Gerlach, H.; Laumann, V.; Martens, S.; Becker, C.F.; Goody, R.S.; Geyer, M. HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat. Chem. Biol., 2010, 6(1), 46-53.
123. Puertollano, R.; Menéndez, M.; Alonso, M.A. Incorporation of MAL, an integral protein element of the machinery for the glycolipid and cholesterolmediated apical pathway of transport, into artificial membranes requires neither of these lipid species. Biochem. Biophys. Res. Commun., 1999, 266(2), 330-333.
124. Walmsley, A.R.; Zeng, F.; Hooper, N.M. The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. J. Biol. Chem., 2003, 278(39), 37241-37248.
125. Fukushima, Y.; Saitoh, T.; Anai, M.; Ogihara, T.; Inukai, K.; Funaki, M.; Sakoda, H.; Onishi, Y.; Ono, H.; Fujishiro, M.; Ishikawa, T.; Takata, K.; Nagai, R.; Omata, M, Asano, T. Palmitoylation of the canine histamine H2 receptor occurs at Cys(305) and is important for cell surface targeting. Biochim. Biophys. Acta, 2001, 1539(3), 181-191.
126. Greaves, J.; Chamberlain, L.H. Palmitoylation-dependent protein sorting. J. Cell. Biol., 2007, 176(3), 249-254.
127. Greaves, J.; Prescott, G.R.; Gorleku, O.A.; Chamberlain, L.H. The fat controller: roles of palmitoylation in intracellular protein trafficking and targeting to membrane microdomains. Mol. Membr. Biol., 2009, 26(1), 67-79.
128. Collawn, J.F.; Stangel, M.; Kuhn, L.A.; Esekogwu, V.; Jing, S.Q.; Trowbridge, I.S.; Tainer, J.A. Transferrin receptor internalization sequence YXRF implicates a tight turn as the structural recognition motif for endocytosis. Cell, 1990, 63(5), 1061-1072.
129. Navratil, A.M.; Bliss, S.P.; Berghorn, K.A.; Haughian, J.M.; Farmerie, T.A.; Graham, J.K.; Clay, C.M.; Roberson, M.S. Constitutive localization of the gonadotropin-releasing hormone (GnRH) receptor to low density membrane microdomains is necessary for GnRH signaling to E.R.K. J. Biol. Chem., 2003, 278(34), 31593-31602.
130. Gimpl, G.; Burger, K.; Fahrenholz, F. Cholesterol as modulator of receptor function. Biochemistry, 1997, 36(36), 10959-10974.
131. Guzzi, F.; Zanchetta, D.; Cassoni, P.; Guzzi, V.; Francolini, M.; Parenti, M.; Chini, B. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene, 2002, 21(11), 1658-1667.
132. Seno, K.; Kishimoto, M.; Abe, M.; Higuchi, Y.; Mieda, M.; Owada, Y.; Yoshiyama, W.; Liu, H.; Hayashi, F. Light-and guanosine 5'-3-O-(thio) triphosphate-sensitive localization of a G protein and its effector on detergent-resistant membrane rafts in rod photoreceptor outer segments. J. Biol. Chem., 2001, 276(24),20813-20816.
133. Rybin, V.O.; Xu, X.; Lisanti, M.P.; Steinberg, S.F. Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J. Biol. Chem., 2000, 275(52), 41447-41457.
134. Kalipatnapu, S.; Chattopadhyay, A. Membrane organization of the serotonin 1A receptor monitored by a detergent-free approach. Cell. Mol. Neurobiol., 2007, 27(4), 1097-1116.
135. Feron, O.; Smith, TW.; Michel, T.; Kelly, R.A. Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes. J. Biol. Chem., 1997, 272(28), 17744-17748.
136. Ushio-Fukai, M.; Hilenski, L.; Santanam, N.; Becker, P.L.; Ma, Y.; Griendling, K.K.; Alexander, R.W. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J. Biol. Chem., 2001, 276(51), 48269-48275.
137. Sabourin, T.; Bastien, L.; Bachvarov, D.R.; Marceau, F. Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts. Mol. Pharmacol., 2002, 61(3), 546-553.
138. Bari, M.; Oddi, S.; De Simone, C.; Spagnolo, P.; Gasperi, V.; Battista, N.; Centonze, D.; Maccarrone, M. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology, 2008, 54(1), 45-50.
139. Oddi, S.; Dainese, E.; Fezza, F.; Lanuti, M.; Barcaroli, D.; De Laurenzi, V.; Centonze, D.; Maccarrone, M. Functional characterization of putative cholesterol binding sequence (CRAC) in human type-1 cannabinoid receptor. J. Neurochem., 2011, 116(5), 858-865.
140. Oddi, S.; Dainese, E.; Sandiford, S.; Fezza, F.; Lanuti, M.; Chiurchiù, V.; Totaro, A.; Catanzaro, G.; Barcaroli, D.; De Laurenzi, V.; Centonze, D.; Mukhopadhyay, S.; Selent, J.; Howlett, A.C.; Maccarrone, M. Palmitoylation of cysteine 415 of helix 8: effect on membrane localisation and signalling of the CB(1) cannabinoid receptor. Br. J. Pharmacol., 2012, 165(8), 2635-2651.
141. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le T, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289(5480), 739-745.
142. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318(5854), 1258-1265.
143. Ohvo, H.; Slotte, J.P. Cyclodextrin-mediated removal of sterols from monolayers: effects of sterol structure and phospholipids on desorption rate. Biochemistry, 1996, 35(24), 8018-8024.
144. Bari, M.; Spagnuolo, P.; Fezza, F.; Oddi, S.; Pasquariello, N.; Finazzi-Agrò, A.; Maccarrone, M. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. J. Immunol., 2006, 177(8), 4971-4980.
145. Maccarrone, M.; De Chiara, V.; Gasperi, V.; Viscomi, M.T.; Rossi, S.; Oddi, S.; Molinari, M.; Musella, A.; Finazzi-Agrò, A.; Centonze D. Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J. Neurochem., 2009, 109(2), 371-381.
146. Sarnataro, D.; Grimaldi, C.; Pisanti, S.; Gazzerro, P.; Laezza, C.; Zurzolo, C.; Bifulco, M. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett., 2005, 579(28), 6343-6349.
147. Sarnataro, D.; Pisanti, S.; Santoro, A.; Gazzerro, P.; Malfitano AM, Laezza, C.; Bifulco, M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol., 2006, 70(4), 1298-1306.
148. Rimmerman, N.; Bradshaw, H.B; Kozela, E; Levy, R; Juknat, A; Vogel, Z. Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1. Br. J. Pharmacol., 2012, 165(8), 2436-2449.
149. Rimmerman, N.; Hughes, H.V.; Bradshaw, H.B; Pazos, M.X.; Mackie, K.; Prieto, A.L.; Walker, J.M. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. Br. J. Pharmacol., 2008, 153(2), 380-389.
150. Szoke, E.; Börzsei, R.; Tóth, D.M.; Lengl, O.; Helyes, Z.; Sándor, Z.; Szolcsányi, J. Effect of lipid raft disruption on TRPV1 receptor activation of trigeminal sensory neurons and transfected cell line. Eur. J. Pharmacol., 2010, 628(1-3), 67-74.
151. Liu, M.; Huang, W.; Wu, D.; Priestley, J.V.TRPV1, but not P2X, requires cholesterol for its function and membrane expression in rat nociceptors. Eur. J. Neurosci., 2006, 24(1), 1-6.
152. Picazo-Juárez, G.; Romero-Suárez, S.; Nieto-Posadas, A.; Llorente, I.; Jara-Oseguera, A.; Briggs, M.; McIntosh, T.J.; Simon, S.A.; Ladrón-de-Guevara, E.; Islas, L.D.; Rosenbaum, T. Identification of a binding motif in the S5 helix that confers cholesterol sensitivity to the TRPV1 ion channel. J. Biol. Chem., 2011, 286(28), 24966-24976.
153. Burgermeister, E.; Tencer, L.; Liscovitch, M. Peroxisome proliferatoractivated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene, 2003, 22(25), 3888-3900.
154. Kotsikorou, E.; Madrigal, K.E.; Hurst, D.P.; Sharir, H.; Lynch, D.L.; Heynen-Genel, S.; Milan, L.B.; Chung, T.D.; Seltzman, H.H.; Bai, Y.; Caron, M.G.; Barak, L.; Abood, M.E.; Reggio, P.H. Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry, 2011, 50(25), 5633-5647.
155. Hanson, M.A.; Cherezov, V.; Griffith, M.T.; Roth, C.B.; Jaakola, V.P.; Chien, E.Y.; Velasquez, J.; Kuhn, P.; Stevens, R.C. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure, 2008, 16(6), 897-905.
156. Pasternack, S.M.; von Kügelgen, I.; Al Aboud, K.; Lee, Y.A.; Rüschendorf, F.; Voss, K.; Hillmer, A.M.; Molderings, G.J.; Franz, T.; Ramirez, A.; Nürnberg, P.; Nöthen, M.M.; Betz, R.C. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet., 2008, 40(3), 329-334.
157. Karnik, S.S.; Ridge, K.D.; Bhattacharya, S.; Khorana, H.G. Palmitoylation of bovine opsin and its cysteine mutants in COS cells. Proc. Natl. Acad. Sci. M.S.A., 1993, 90(1), 40-44.
158. Waheed, A.A.; Jones, T.L. Hsp90 interactions and acylation target the G protein Galpha 12 but not Galpha 13 to lipid rafts. J. Biol. Chem., 2002, 277(36), 32409-32412.
159. Olsson, S.; Sundler, R. The role of lipid rafts in LPS-induced signaling in a macrophage cell line. Mol. Immunol., 2006, 43(6), 607-612.
160. Dhungana, S.; Merrick, B.A.; Tomer, K.B.; Fessler, M.B. Quantitative proteomics analysis of macrophage rafts reveals compartmentalized activation of the proteasome and of proteasome-mediated ERK activation in response to lipopolysaccharide. Mol. Cell. Proteomics., 2009, 8(1), 201-213.
161. Yan, J.; Li, Q.F.; Wang, L.S.; Wang, H.; Xiao, F.J.; Yang, Y.F.; Wu, C.T. Methyl-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling. Anticancer Drugs, 2012, 23(1), 22-31.
162. Kozela, E.; Pietr, M.; Juknat, A.; Rimmerman, N.; Levy, R.; Vogel, Z. Cannabinoids Delta(9)-tetrahydrocannabinol and Cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem., 2010, 285(3), 1616-1626.
163. Rimmerman, N.; Juknat, A.; Kozela, E.; Levy, R.; Bradshaw, H.B.; Vogel, Z. The Non-Psychoactive Plant Cannabinoid, Affects Cholesterol Metabolism-Related Genes in Microglial Cells. Cell. Mol. Neurobiol., 2011, 31(6), 921-930.
164. Lynch, D.L.; Reggio, P.H. Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J. Comput. Aided. Mol. Des., 2006, 20(7-8), 495-509.
165. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics, 2006, 22(2), 195-201.
166. Zinchuk, V; Zinchuk, O. Quantitative colocalization analysis of confocal fluorescence microscopy images. Curr. Protoc. Cell. Biol., 2008, 4, 4.19.